rs2954021 — TRIB1

TRIB1 — The Liver's Hidden Triglyceride Dial

The TRIB1 gene¹¹ TRIB1 gene
tribbles pseudokinase 1, a regulatory scaffold protein expressed predominantly in the liver sits at one of the most replicated triglyceride loci in the human genome. Despite encoding a pseudokinase — a protein that resembles a kinase but lacks catalytic activity — TRIB1 has a powerful indirect effect on blood fat levels through its role in controlling hepatic lipid production. The rs2954021 variant, located near the TRIB1 gene on chromosome 8q24, was first identified in a landmark 2008 Nature Genetics GWAS and has since been replicated across dozens of studies and hundreds of thousands of participants.

The Mechanism

TRIB1 acts as a scaffold protein that recruits the COP1 E3 ubiquitin ligase²² COP1 E3 ubiquitin ligase
an enzyme complex that tags proteins for destruction to its substrates, most importantly C/EBPα³³ C/EBPα
CCAAT/enhancer binding protein alpha, a transcription factor that controls the expression of enzymes involved in fatty acid and glucose metabolism in the liver. By promoting C/EBPα degradation, TRIB1 modulates the activity of genes driving de novo lipogenesis⁴⁴ de novo lipogenesis
the liver's process of converting carbohydrates and glucose into triglycerides for storage or export as VLDL particles.

The rs2954021 variant is located in the regulatory region near TRIB1 and is thought to alter the level or timing of TRIB1 expression in hepatocytes. G allele carriers show higher circulating triglycerides and altered LDL levels, consistent with increased hepatic VLDL output. The A allele, while not the major triglyceride risk allele, is strongly associated with elevated liver enzymes (ALT and alkaline phosphatase) and increased susceptibility to nonalcoholic fatty liver disease⁵⁵ nonalcoholic fatty liver disease
NAFLD, the accumulation of excess fat in liver cells not caused by alcohol. This dual-allele risk pattern reflects the complexity of hepatic lipid handling: too much triglyceride export (G allele) raises cardiovascular risk, while impaired export or increased lipid accumulation (A allele) drives liver damage.

The Evidence

The TRIB1 locus was independently discovered by two GWAS published simultaneously in Nature Genetics in 2008 — Kathiresan et al. (8,816 discovery + 18,554 replication subjects)⁶⁶ Kathiresan et al. (8,816 discovery + 18,554 replication subjects)
Six new loci associated with blood LDL cholesterol, HDL cholesterol or triglycerides in humans and Willer et al. (8,816 subjects)⁷⁷ Willer et al. (8,816 subjects)
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Both studies identified 8q24 near TRIB1 as a novel triglyceride locus, and the association has been replicated in every major subsequent lipid GWAS.

The Global Lipids Genetics Consortium (2013)⁸⁸ Global Lipids Genetics Consortium (2013)
Discovery and refinement of loci associated with lipid levels — the largest lipid GWAS at the time, with over 100,000 participants confirmed TRIB1 as one of the robustly replicated triglyceride loci. The Waterworth et al. (2010) study of 17,723 participants⁹⁹ Waterworth et al. (2010) study of 17,723 participants
showed TRIB1 associations with both lipid traits and coronary artery disease risk, establishing the cardiovascular relevance of elevated triglycerides at this locus.

A large GWAS of 61,089 individuals found the rs2954021-A allele was associated with elevated ALT (p=5×10⁻⁹, beta 1.6%) and alkaline phosphatase (p=2×10⁻¹³, beta 1.4%), implicating TRIB1 in liver cell stress independent of the circulating lipid effects. A Japanese case-control study¹⁰¹⁰ Japanese case-control study
540 NAFLD cases and 1,012 controls found the A allele significantly associated with nonalcoholic fatty liver disease (p=4.5×10⁻⁵), and a 2023 NAFLD GWAS meta-analysis¹¹¹¹ 2023 NAFLD GWAS meta-analysis
66,814 imaging samples confirmed TRIB1 as one of 17 validated NAFLD loci, mechanistically linked to hepatic de novo lipogenesis via glucose metabolism pathways.

Practical Actions

The triglyceride-raising effect of the G allele is meaningfully modulated by diet and lifestyle. Triglyceride levels are among the most diet-responsive of all lipid parameters: refined carbohydrates, sugar, and alcohol are the primary dietary drivers of elevated triglycerides, often more so than dietary fat. G allele carriers benefit substantially from limiting added sugars and refined carbohydrates, moderating alcohol, and increasing omega-3 fatty acid intake (EPA and DHA from fatty fish or fish oil supplements have established triglyceride-lowering effects at doses of 2–4 g/day). Aerobic exercise also directly lowers triglycerides by increasing lipoprotein lipase activity.

For A allele homozygotes with elevated liver enzymes or a family history of fatty liver disease, limiting fructose (a key substrate for hepatic de novo lipogenesis), moderating alcohol strictly, and prioritizing weight management are the most impactful interventions. Baseline measurement of liver enzymes (ALT, AST, GGT) and a fasting lipid panel provides essential context for tracking whether dietary changes are improving liver and lipid health.

Interactions

TRIB1 rs2954021 acts within the broader hepatic lipid metabolism network. GCKR rs1260326 (glucokinase regulatory protein) is a well-established pathway partner that also modulates hepatic triglyceride production — GCKR and TRIB1 variants show independent effects and may compound. APOB rs693 and SORT1 rs12740374 are other LDL-related loci that can combine with TRIB1 effects on atherogenic lipoprotein particles. Carriers of multiple triglyceride-raising variants at these loci face a cumulative lipid burden that warrants a broader lipid panel (including direct LDL measurement and ideally ApoB quantification) rather than standard total cholesterol screening.